Purpose: To investigate systemic leucocyte activity in subtypes of age-related macular degeneration (AMD) and onset of neovascular AMD. Methods: Patients with early and late AMD and age-matched control individuals were recruited consecutively, and venous blood was sampled for differential leucocyte counts. Patients with neovascular AMD were grouped based on time of blood sampling in relation to diagnosis of neovascular AMD: diagnosis of new neovascular AMD more than 30 days before blood sampling, within 30 days of blood sampling and more than 30 days after blood sampling. Results: Of 347 recruited participants, 330 fulfilled the eligibility criteria (77 agematched controls, 33 with early AMD, 56 with geographic atrophy and 164 with neovascular AMD). We did not find any differences in the differential counts between patients at different stages of AMD and age-matched control individuals. However, lymphocyte and monocytes-basophils-eosinophils mixed (MXD) counts were both significantly increased in patients with new neovascular AMD. Among these patients; higher MXD correlated with lower BCVA, larger central foveal thickness and larger total lesion size; higher lymphocytes correlated with smaller total lesion size; higher neutrophils correlated with CNV lesion size; and higher neutrophil-to-lymphocyte ratio correlated with larger lesion size. Conclusions: Systemic leucocyte activity is associated with onset of CNV in patients with AMD and correlate with lesion size and BCVA, which suggest that acute systemic immune activity may play a role in neovascular flaring of AMD.
Introduction
Age-related macular degeneration (AMD) is a leading cause of irreversible visual impairment among the elderly worldwide (Bloch et al. 2012; Lindekleiv & Erke 2013; Hu et al. 2016) . Early signs of AMD differ from that of normal macular ageing (Subhi et al. 2016) by the presence of drusenlipid and protein containing deposits underneath the retinal pigment epithelium (RPE) -suggested to be a result of uncompensated oxidative damage and linked to complement dysregulation (Anderson et al. 2010) . Early AMD progresses to its late stage among 5% in 5 years and 15% in 15 years (Mitchell et al. 2002; Klein et al. 2007b) , which can be geographic atrophy with islands of photoreceptor, RPE and choriocapillaris loss; or neovascular AMD. In neovascular AMD, new vessels form in the choroid that underlies macular neuroretina and break through the Bruch's membrane to grow under and in the retina. These new and immature vessels bleed and leak, damaging the surrounding retinal tissue. All of these morphological changes manifest as the hallmark symptoms of neovascular AMD: metamorphopsia, blurred vision or central scotoma. If the newly formed fibrovascular tissue is left untreated, formation of fibrotic scars will ravage the macular tissue leading to severe visual impairment within a few years (Wong et al. 2008) . Time -even few weeks -plays an important role in the prognosis and treatment of neovascular AMD (Wong et al. 2008; Rasmussen et al. 2015) . Treatment is more potent when given as soon as possible after diagnosis of neovascular AMD (Rasmussen et al. 2015) , possibly due to a timely course of actions in the neovascularization pathogenesis (Fauser et al. 2015; Hautam€ aki et al. 2015; Kubicka-Trza z ska et al. 2016) .
Increasing evidence find inflammation and dysfunction of immune cells in patients with neovascular AMD (Singh et al. 2012; Falk et al. 2014a; Faber et al. 2015; Haas et al. 2015) , but whether these changes undergo change with time remains largely unknown. However, other neurodegenerative inflammatory diseases do demonstrate timely course of actions. One example is multiple sclerosis, where immune cells infiltrate and damage the central nervous system in phases of relapse and remission demonstrating a pronounced timely course of action. Relapses are associated with systemic immune activation (Steelman 2015) , for example Buljevac et al. (2002) found that from 2 weeks before and until 5 weeks after onset of a clinical infection, the risk of relapse was doubled. Similar findings are reported among patients with Alzheimer's in which onset of delirium results in rapid disease progression and decline in cognitive abilities (Fong et al. 2009 ). Infection and delirium are examples that give rise to highgrade inflammation, and studies also suggest that low-grade inflammation may contribute to a progression albeit in a less powerful manner (Perry 2010) . As immune dysfunction and inflammation play a role in AMD, there is a theoretical reason to assume that time of progression in AMD could be associated with increased systemic immune activity. Interestingly, patients with late stage of AMD have an increased rate of comorbidities with known inflammatory components (Zlateva et al. 2007; Kao et al. 2015) .
Elucidation of vascular endothelial growth factor's (VEGF) role in neovascular AMD has been a game changer for the treatment of neovascular AMD. Retinal pigment epithelium (RPE) produces VEGF as a result of the local hypoxic and inflammatory environment that is promoted by drusen, which facilitates the formation of choroidal neovascularization (CNV); however, it still remains to be understood why some patients can have a drusenoid macula for many years without developing CNV and what drives the onset of CNV formation in humans. Animal models suggest that in the acute phase of CNV, immune cells are recruited to the lesion site and that the nature of the different immune cells determines the aftermath (Espinosa-Heidmann et al. 2003; Sakurai et al. 2003; TsutsumiMiyahara et al. 2004; Zhou et al. 2005) . Monocytes and neutrophils are suggested to play a role in CNV formation as they infiltrate CNV lesions, and depletion of monocytes is shown to reduce lesion size (Espinosa-Heidmann et al. 2003; Sakurai et al. 2003; Tsutsumi-Miyahara et al. 2004; Zhou et al. 2005) . Lymphocytes -T cells in particular -do not infiltrate CNV lesions, but play a significant role in the complex immune play by changing the cytokine expression pattern of the RPE in a way that promotes monocyte chemotaxis and activation (Tsutsumi-Miyahara et al. 2004; Juel et al. 2011 Juel et al. , 2012 . Taken together these studies strongly suggest that immune cells play a role in the acute phase of laser-induced CNV in animal models, but to the best of our knowledge, studies have not investigated what happens in humans with AMD in the acute phase in the onset of choroidal neovascularization and how that affects immune cells in the systemic circulation.
In this study, we explored the systemic leucocyte differential counts in patients with AMD. We compared healthy age-matched controls with AMD with patients with early AMD, geographic atrophy and neovascular AMD, which did not reveal any systemic leucocyte recruitment. However, blood sampled from patients with new neovascular AMD around their time of diagnosis showed a higher systemic monocyte and lymphocyte count. Among these patients; higher monocyte count was correlated with lower best-corrected visual acuity (BCVA), larger central foveal thickness and larger total lesion size; higher lymphocytes were correlated with smaller total lesion size and almost statistically significant with smaller CNV size; and higher neutrophils count was correlated with larger CNV lesion size. Our findings suggest that new CNV in patients with AMD is associated with a systemic immune response.
Patients and Methods
We consecutively recruited patients and visitors from our retinal clinic for possible participation in this crosssectional study. First participant was recruited in February 2011, and last participant was recruited in January 2016. All participants had the nature of the study explained, and oral and written consent was obtained a priori for participation. The study is approved by the Danish Data Protection Agency and the Regional Committee of Ethics in Research of the Region of Zealand (Journal Number SJ-142, SJ-379, and SJ-385), and we followed the ethical principles for medical research involving human subjects stated in the Declaration of Helsinki.
Examination, diagnosis and eligibility
All participants were examined using slit-lamp bio-microscopy, digital fundus photography and spectral domain optical coherence tomography (SD-OCT). Patients suspected of choroidal neovascularization were also examined using fluorescein and indocyanine green angiography. Best-corrected visual acuity (BCVA) in each eye was measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) chart (Kaiser 2009 ).
Eyes were graded according to the Clinical Age-Related Maculopathy Grading System (CARMS; Seddon et al. 2006) . Grade 1 was defined as 0-9 small drusen without pigment abnormalities. Grade 2 was defined as 10 or more small drusen, <15 intermediate drusen or pigment abnormalities (hyper-and hypopigmentation), and grade 3 was defined as 15 intermediate drusen or any large drusen. Grade 4 was defined as geographic atrophy involving macular centre or non-macular geographic atrophy of 350 lm 2 or more. Grade 5 was defined as neovascular AMD including non-drusenoid pigment epithelial detachments, serous retinal detachments, choroidal neovascular membrane with subretinal or subretinal pigment epithelium haemorrhages or fibrosis. The highest CARMS grade received from both eyes was used for participant classification into no AMD (highest CARMS grade 1), early AMD (highest CARMS grade 3), geographic atrophy (highest CARMS grade 4) and neovascular AMD (highest CARMS grade 5). Eligible participants were either patients with early AMD, geographic atrophy, neovascular AMD or elderly individuals ≥70 years old with no retinal disease and CARMS 1 grading which we used as an age-matched control.
All participants were interviewed to get medical history and current medication use, which was confirmed by data from the participants' electronic patient records. We also noted body mass index using weight and height, weekly alcohol consumption (1 unit = 12 g ethanol), smoking status (Freedman et al. 2008) and physical activity (Subhi et al. 2014b ). We noted any progression of AMD from electronic patient records and images. We did not include participants with any known immune disease or cancer, any immune modulating therapy for any reason or any ongoing infection to avoid interference with an acute immune response. Venous blood was sampled in a lithium heparin-coated tube for plasma C-reactive protein (CRP) measurements to support the decision of whether to exclude participants with an acute immune response (Rifai & Ridker 2001) .
Leucocyte differential count
We sampled venous blood from antecubital veins in a ethylenediaminetetraacetic acid (EDTA)-coated tube and did differential counts within 2 hr to avoid leucocyte activation or apoptosis. We used an automated haematology analyzer Sysmex KX-21N TM (Sysmex Corporation, Kobe, Japan), which uses direct current detection method with coincidence correction to measure white blood cells (WBC) count, lymphocytes count and percentage, neutrophils count and percentage, and monocytes-basophils-eosinophils mixed (MXD) count and percentage. In normal adults, the MXD population will primarily consist of monocytes as the normal reference ranges for monocytes, basophils and eosinophils are 0.2-1.0 9 10 9 cells/l, 0.02-0.1 9 10 9 cells/l and 0.2-0.5 9 10 9 cells/l, respectively. Sample volume for count was 50 ll. Data output was available as number of cells/ll and as percentage of WBC for lymphocytes, neutrophils and MXD. Neutrophil-to-lymphocyte ratio was calculated by dividing the respective number of cells/ll.
Data analyses and statistics
Participant characteristics were summarized in groups defined by stage of AMD. We compared leucocyte differential counts between these groups to investigate any stage-specific difference (no AMD versus early AMD versus geographic atrophy versus neovascular AMD). Then, patients with neovascular AMD were grouped based on when blood was sampled in relation to when the patient received a diagnosis of neovascular AMD in order to investigate any timely relationship with the differential counts. In case both eyes were diagnosed with neovascular AMD, we calculated time difference between blood sampling and time of diagnosis for both eyes and used the shortest time difference. Three categories were made for data analysis: diagnosis of new neovascular AMD more than 30 days before blood sampling (old neovascular AMD), within 30 days of blood sampling (new neovascular AMD) and more than 30 days after blood sampling (future neovascular AMD). When fibrotic and old neovascular AMD was diagnosed, time of diagnosis was categorized as 'old'. Group of new neovascular AMD was investigated in depth to look at potential relationships between leucocyte differential counts and foveal morphology (central foveal thickness measured using the OCT scans), and CNV and total lesion size (measured on the angiography and the OCT scans). As BCVA does not strictly follow foveal morphology (Subhi et al. 2014a; Achiron et al. 2015) , we also looked at whether differential counts correlated with the BCVA. Up to 30 days before blood sampling was categorized as new neovascular AMD to account for the variation in the time of delay between onset of new CNV, onset of symptoms, visiting an ophthalmologist and being referred to our hospital clinic. The period of 30 days after blood sampling was based on experiences from mice studies with experimental laser-induced CNV where immune cells remain active for a week Tsutsumi-Miyahara et al. 2004 ), and we allowed a longer period to account for potential human differences.
Categorical variables are presented in numbers and percentages, and potential associations were investigated using v 2 -test, or Fisher's exact test when dealing with small groups. Continuous variables that were normally distributed are presented using mean and standard deviation (SD) and compared using parametric tests and otherwise using median and interquartile range (IQR) and compared using nonparametric tests. As differential counts were not normally distributed, all correlations were performed using twotailed Spearman's correlation. Data were analysed using SPSS 23 (IBM Corporation, Armonk, NY, USA). p-Values below 0.05 are interpreted as indication of statistical significance.
Results
We enrolled a total of 347 participants. Two were excluded due to the presence of immune disease and, another 15 were excluded due to possible ongoing infection or immune disease as they had plasma CRP >15 mg/l (n = 15) or WBC >12 9 10 9 l À1 (n = 5). A total of 326 participants were included in our analyses, of which 76 were healthy control individuals, 33 were patients with early AMD, 56 were patients with geographic atrophy and 161 were patients with neovascular AMD. Participants with different stages of the disease did not differ significantly in terms of age, sex, BMI, physical activity or comorbidities (Table 1) . Alcohol use did not differ between healthy controls and patients with geographic atrophy or neovascular AMD, but patients with early AMD had a slightly higher weekly consumption. We did not find any significant differences between participants with different stages of AMD and WBC, lymphocytes (% and count), MXD (% and count) and neutrophils (% and count; Table 2 ). Values had ranges and distributions similar of what we expected from normal elderly individuals. We had six patients with neovascular AMD that were diagnosed >30 days after blood sampling (one patient with geographic atrophy at time of blood sampling and remaining five were patients with neovascular AMD in one eye only at time of blood sampling), 37 with new neovascular AMD that were diagnosed within AE30 days of blood sampling (median 0 days, IQR: 0 to 0 days) and 119 with old neovascular AMD that were diagnosed >30 days before blood sampling. These groups did not differ in terms of age (p = 0.095, one-way analysis of variance), sex (p = 0.183, Fisher's exact test), BMI (p = 0.084, one-way analysis of variance), alcohol (p = 0.072, Kruskal-Wallis test), physical activity (p = 0.485, Fisher's exact test), smoking (p = 0.259, Fisher's exact test) or comorbidities (p = 0.726, p = 0.278, p = 0.833, Fisher's exact test, for hypercholesterolemia, cardiovascular diseases and type 2 diabetes, respectively) besides hypertension (p = 0.036, Fisher's exact test) which was slightly more common in the group of new neovascular AMD.
We found that patients with new neovascular AMD had higher counts in WBC (p = 0.042, Kruskal-Wallis test), lymphocytes (p = 0.019, Kruskal-Wallis test) and MXD (p = 0.025, KruskalWallis test; Table 3 ). The difference in group medians was considerable (10 -20%). Other differential counts did not differ significantly between the groups. A small sample of these patients (n = 7)
had their blood sampled again later (>30 days), which we used for samesubject comparisons of leucocyte differential counts (Table 4) . Despite the small sample, MXD count was significantly higher within AE30 days of newly diagnosed neovascular AMD than later (p = 0.031, one-sample t-test).
We then looked at potential correlations between differential counts and anatomical parameters in patients with new neovascular AMD (Fig. 1) . We found that higher MXD correlated larger central foveal thickness (q = 0.330; p = 0.046, count, Spearman's correlation) and larger total lesion size (q = 0.356; p = 0.030, count, Spearman's correlation). We also found that higher percentage and count of neutrophils correlated with larger CNV size (q = 0.423, p = 0.028; q = 0.430, p = 0.025; percentage and count, respectively, Spearman's correlation). Percentage of lymphocytes correlated negatively with total lesion size (q = À0.403; p = 0.013, Spearman's correlation) and almost at statistical significant level with CNV size (q = À0.376; p = 0.053, Spearman's correlation). Some of these correlations had a magnitude that significantly affected the BCVA: higher MXD correlated with lower BCVA (q = À0.435, p = 0.007; q = À0.375, p = 0.022; percentage and count, respectively, Spearman's correlation).
Discussion
This study suggests that systemic leucocyte activity is associated with diagnosis of new neovascular AMD. Patients with new neovascular AMD had higher MXD count, which may primarily reflect a systemic monocyte activity and higher lymphocyte count. Seven of these patients had a differential count at another time-point >30 days of blood sampling that we used to look at samesample differences, which revealed that even in a very small sample, MXD count was significantly higher around the time of diagnosis. Differential counts in new neovascular AMD also correlated with clinical relevant measures for neovascular AMD: higher MXD correlated with lower BCVA, larger central foveal thickness and larger total lesion size; higher lymphocytes correlated with smaller total lesion size and almost significantly with smaller CNV size; higher neutrophils correlated with larger CNV size; and higher neutrophil-to-lymphocyte ratios correlated with larger lesion size and almost significantly with larger CNV size. Ageing induces changes of the immune system, one of which are lower proportion of T cells that express CD28 but instead upregulate expression of CD56 -an ageing phenomenon accelerated in patients with AMD (Faber et al. 2013 ). These CD56 + T cells produce cytokines such as the macrophage inflammatory protein-1b that is chemotactic for macrophages (Campbell et al. 2001 (Falk et al. 2014a,b; Chen et al. 2016) . CX 3 CR1 and CCR2 are both shown to be involved in drusen formation and RPE changes in animal models, and it is suggested that dysfunction of this system may play a role in monocyte recruitment and macrophage infiltration of the macula Combadi ere et al. 2007; Luhmann et al. 2009 ). Adequate CXCR3 function is needed to balance the angiogenic drive (Bodnar et al. 2006; Yates-Binder et al. 2012 ). CD46 and CD59 are complement regularity proteins that are expressed lower on CD14 + monocytes in patients with AMD (Singh et al. 2012) , which strips the patients from the proteins' otherwise protective role inhibiting formation of the membrane attack complex (Bora et al. 2010; Lyzogubov et al. 2014) . CD11b is expressed on monocytes to facilitate adhesion and migration and play a critical role in antigen clearance at sites of inflammation through VEGF expression (Kataru et al. 2009 ). Altered expression of CD11b + monocytes and co-expression the retinal microglia regulator CD200 is reported in patients with AMD Lechner et al. 2015) . Also, increased expression of CD16 high HLA-DR À is reported in neutrophils of patients with AMD (Lechner et al. 2015) , which may be a sign of increased neutrophil activity that is not yet fully understood (Moulding et al. 1999; Pillay et al. 2012 ). These studies collectively demonstrate systemic alterations on circulating immune cells in AMD. On the other hand, studies of unspecific immune cell count yield more inconclusive results (Table 5 ). The presence of drusen and signs of early AMD does not seem to influence differential counts, while some studies find that neovascular AMD is associated with a slight increase in WBC count (Klein et al. 1993 (Klein et al. , 2007a Wang et al. 2008) , which may reflect that some systemic immune activity may be present in neovascularization. Another important difference between the studies may be whether or not they Table 4 . In a small sample (n = 7) of participants, leucocyte differential counts were available at two time-points in which one was within AE30 days of newly diagnosed neovascular AMD and the other >30 days, which was used to calculate same-sample differences.
Mean ( exclude cases with increased CRP and at which concentration. Excluding cases based on a too low CRP level may lead to false-negative findings when studying systemic inflammation. Some studies of inflammation (Tegeler et al. 2016) exclude cases with CRP >10 mg/l, which may be low limit for a study of inflammation considering that the reference interval is <10.5 mg/l in individuals without an ongoing infection (Erlandsen & Randers 2000) . On the other hand, not excluding cases with very high CRP may lead to inclusion of cases with an ongoing infection that leads to transient but significant changes of the differential counts.
Murine models of laser-induced CNV provide insights into the acute processes of CNV (Espinosa-Heidmann et al. 2003; Sakurai et al. 2003; Tsutsumi-Miyahara et al. 2004; Zhou et al. 2005) . Macrophages invade the site of injury within the first day, peak in number at 3 days and disappear after a week . Systemic monocyte depletion leads to fewer macrophages at site of injury, reduction in VEGF protein level and CNV size (Espinosa-Heidmann et al. 2003; Sakurai et al. 2003) . Neutrophils also invade site of injury within the first day of injury, but peak and disappear slightly faster, and a general depletion of neutrophils also showed reduction of CNV size (Tsutsumi-Miyahara et al. 2004 ). Lymphocytes do not infiltrate the CNV lesion, but may still play a role in the acute phase that remains to be understood in detail (TsutsumiMiyahara et al. 2004; Juel et al. 2011 Juel et al. , 2012 . Interestingly, these findings are Fig. 1 . Correlation of leucocyte differential count with foveal morphology, and choroidal neovascularization (CNV) and total lesion size in patients with newly diagnosed neovascular age-related macular degeneration (n = 37). Higher monocytes-basophils-eosinophils mixed correlated with larger central foveal thickness, and larger total lesion size; higher lymphocytes correlated with smaller total lesion size and almost significantly with smaller CNV size; higher neutrophils correlated with larger CNV size; and higher neutrophil-to-lymphocyte ratios correlated with larger lesion size and almost significantly with larger CNV size. Fluorescein and indocyanine green angiography images were accessible and of sufficient quality for CNV lesion size estimation for 27 participants. All correlations are based on the twotailed Spearman's rank correlation. not specific to retinal studies and are also demonstrated in brain research, for example in mice models of cerebral ischaemia macrophage depletion reduce myelin damage and microglia activation (Ma et al. 2016 ) and neutrophil or T-cell depletion reduce infarct volumes and neurological deficits (Yilmaz et al. 2006; Liesz et al. 2009; Herz et al. 2015) . Findings from these animal models of CNV and nerve damage strongly suggest that the severity of angiogenesis and nerve injury is correlated to the number of cells available in the systemic circulation that is mobilized to the site of damage and may explain why we find higher counts in patients with recent onset of CNV. Possible explanation is that a transient increase in cell numbers combined with the altered expression pattern of systemic immune cells in patients with AMD amplifies the pro-inflammatory activity triggering the CNV. We find that higher monocyte count is correlated with larger central foveal thickness and larger total lesion size, that higher neutrophil count is correlated with larger CNV size and that lymphocytes are inversely correlated with total lesion size which may be due to more CX 3 CR1 + and CXCR3 + T cells to control the angiogenic drive. This may also explain why we find that increased neutrophil-to-lymphocyte ratio, which may reflect the temporal systemic inflammatory state, correlates with CNV and lesion size; and interestingly, similar links to disease severity are demonstrated in studies of acute coronary syndrome (Tamhane et al. 2008) , cancer (Templeton et al. 2014 ) and Alzheimer's disease (Rembach et al. 2014) .
It is important to consider the limitations of our study when interpreting its results. We assume that time of onset of neovascular AMD somewhat equate with time of diagnosis, which is an approximation as there is a delay between the patients first noticing their symptoms and deciding to see their physician and the physician diagnosing a retinal disease and referring to our specialists. There is a possibility that some of our patients had their onset of neovascularization long before their visit to our department, which would mean that the group which we define as having a recent onset of neovascular AMD is contaminated with patients with an actual onset long before; however, this bias would theoretically attenuate the differences between group and differences we find in spite of this attenuation may reflect strong actual differences. We measured MXD which also includes basophils and eosinophils, which should play a minor role, but still is a source of bias to our results. Participants with an immune disease and an acute immune response were excluded, which is a strength of this study as it attenuates potential influences from concomitant immune diseases but also excludes cases with AMD in which systemic immune activation may have lead to CNV formation. Finally, some of our comparisons and groups are based on small numbers, which only allows our study to be exploratory and not confirmatory of nature.
In conclusion, we find that new neovascular AMD is associated with systemic leucocyte activity and that systemic leucocyte activity correlates with how the CNV manifests in the retina in terms of foveal thickness, CNV size and total lesion size -all of which are contributors to the clinically measured BCVA. Further studies are needed to dig further into what happens in the systemic circulation of patients with AMD in their acute phase of CNV and whether an immune intervention may prove relevant. 
